1.
#TumorBoardTuesday
@TumorBoardTues
It started as a virtual interaction, now we finally met. A face-to-face @TumorBoardTues meeting Such an honor to… twitter.com/i/web/status/1…
Retweet of status by @FogacciJoao
2.
#TumorBoardTuesday
@TumorBoardTues
...and next week, @glovedoc & @arkhaki present us with the latest advances in progressing #urothelialcarcinoma. G… twitter.com/i/web/status/1…
3.
4.
5.
6.
7.
#TumorBoardTuesday
@TumorBoardTues
There’s no planned #TumorBoardTuesday discussion for January 24, but #PancChat has one at 8pm ET!!
Catch up on… twitter.com/i/web/status/1…
Catch up on… twitter.com/i/web/status/1…
#TumorBoardTuesday
@TumorBoardTues
1/5 #TumorBoardTuesday
A discussion on HER2- mBC and the role of PARPi led by @jane_meisel @quirogad
Here’s… twitter.com/i/web/status/1…
A discussion on HER2- mBC and the role of PARPi led by @jane_meisel @quirogad
Here’s… twitter.com/i/web/status/1…
#TumorBoardTuesday
@TumorBoardTues
#TumorBoardTuesday #OncTwitter
We've️the exciting newfor advanced HER2+ #breastcancer
But is HER2soas to h… twitter.com/i/web/status/1…
We've️the exciting newfor advanced HER2+ #breastcancer
But is HER2soas to h… twitter.com/i/web/status/1…
#TumorBoardTuesday
@TumorBoardTues
This. Is. Why. We. Try (when possible). To Wait. For. The. NGS. Hard though when there's a very high PD-L1 TPS t… twitter.com/i/web/status/1…
Retweet of status by @JohnEbbenMDPhD
#TumorBoardTuesday
@TumorBoardTues
#TumorBoardTuesday
Thankfully, the survival rate for patients with non-small cell lung🫁cancer has clearly beeni… twitter.com/i/web/status/1…
Thankfully, the survival rate for patients with non-small cell lung🫁cancer has clearly beeni… twitter.com/i/web/status/1…
Retweet of status by @TumorBoardTues
8.
9.
10.
11.
#TumorBoardTuesday
@TumorBoardTues
That’s the hour
Thank youfor an outstanding & informative #TumorBoardTuesday!!
Be on the lookout for C… twitter.com/i/web/status/1…
Thank youfor an outstanding & informative #TumorBoardTuesday!!
Be on the lookout for C… twitter.com/i/web/status/1…
Retweet of status by @TumorBoardTues
#TumorBoardTuesday
@TumorBoardTues
@TumorBoardTues 4/16 #TumorBoardTuesday
Mini tweetorial 2
Different Types of EGFR mutations
Classic Ac… twitter.com/i/web/status/1…
Mini tweetorial 2
Different Types of EGFR mutations
Classic Ac… twitter.com/i/web/status/1…
Retweet of status by @ShrutiPatelMD
#TumorBoardTuesday
@TumorBoardTues
5/15 #TumorBoardTuesday #LCSM
Mini tweetorial 3
Immunotherapy & MET:
METex14 may express PDL1 but inconsist… twitter.com/i/web/status/1…
Mini tweetorial 3
Immunotherapy & MET:
METex14 may express PDL1 but inconsist… twitter.com/i/web/status/1…
#TumorBoardTuesday
@TumorBoardTues
4/15 #TumorBoardTuesday
Mini tweetorial 2
MET Ex 14 splicing error leads to
ubiquitination & degradation
M… twitter.com/i/web/status/1…
Mini tweetorial 2
MET Ex 14 splicing error leads to
ubiquitination & degradation
M… twitter.com/i/web/status/1…
...but wait! There's more!
1.
fakhright
@fakhright
astaghfirullah peng.krim guaaaaaaaa..............a *salto sambil solat*
